MA27593A1 - Derives de n-acyle piperidine utilises comme ligands du recepteur de la melanocortine dans le traitement de troubles de l'alimentation. - Google Patents
Derives de n-acyle piperidine utilises comme ligands du recepteur de la melanocortine dans le traitement de troubles de l'alimentation.Info
- Publication number
- MA27593A1 MA27593A1 MA27917A MA27917A MA27593A1 MA 27593 A1 MA27593 A1 MA 27593A1 MA 27917 A MA27917 A MA 27917A MA 27917 A MA27917 A MA 27917A MA 27593 A1 MA27593 A1 MA 27593A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- receptor ligands
- melanocortin receptor
- piperidine derivatives
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
Abstract
La présente invention concerne des composés comprenant un noyau pipéridine substitué en position 4 et lié à un noyau hydrocarbyle non substitué. Ces composés, y compris leurs formes énantiomères et diastéréoisomères et leurs sels pharmaceutiquement acceptables, sont représentés par la formule (I), dans laquelle, de préférence, R est aryle substitué, W1 est une unité carbocyclique et W2 est une unité comprenant un hétéroatome. Lesdits composés sont des ligands du récepteur de la mélanocortine utiles dans le traitement de troubles de l'alimentation.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37672702P | 2002-04-30 | 2002-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27593A1 true MA27593A1 (fr) | 2005-11-01 |
Family
ID=29401395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27917A MA27593A1 (fr) | 2002-04-30 | 2004-10-27 | Derives de n-acyle piperidine utilises comme ligands du recepteur de la melanocortine dans le traitement de troubles de l'alimentation. |
Country Status (19)
Country | Link |
---|---|
US (2) | US20040010010A1 (fr) |
EP (1) | EP1499314A1 (fr) |
JP (1) | JP2005525410A (fr) |
KR (1) | KR20040104671A (fr) |
CN (1) | CN1655785A (fr) |
AR (1) | AR039780A1 (fr) |
AU (1) | AU2003234094B2 (fr) |
BR (1) | BR0309748A (fr) |
CA (1) | CA2483806A1 (fr) |
IL (1) | IL164697A0 (fr) |
MA (1) | MA27593A1 (fr) |
MX (1) | MXPA04010762A (fr) |
NO (1) | NO20045126L (fr) |
PE (1) | PE20040375A1 (fr) |
PL (1) | PL373575A1 (fr) |
RU (1) | RU2004134719A (fr) |
TW (1) | TW200404543A (fr) |
WO (1) | WO2003092690A1 (fr) |
ZA (1) | ZA200408528B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
FR2870244B1 (fr) * | 2004-05-11 | 2011-01-07 | Centre Nat Rech Scient | Conjugues dipeptidiques antagonistes de l'alpha-msh |
FR2870243B1 (fr) | 2004-05-11 | 2010-11-19 | Centre Nat Rech Scient | Conjugues tripeptidiques agonistes de la msh |
EP1773338B1 (fr) | 2004-07-19 | 2010-01-06 | Merck & Co., Inc. | Derives de piperidine acyles utilises en tant qu'agonistes du recepteur de la melanocortine 4 |
FR2873690B1 (fr) * | 2004-07-29 | 2006-10-13 | Sanofi Synthelabo | Derives d'oxopiperidine, leur preparation et leur application en therapeutique |
US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2625877A1 (fr) | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Derives de spiropiperidine acyles utilises en tant que modulateurs vis-a-vis du recepteur de melanocortine-4 |
EP1826201A1 (fr) * | 2006-02-23 | 2007-08-29 | Santhera Pharmaceuticals (Schweiz) AG | Dérivés substitués de la phenylpipéridine comme modulateurs du récepteur de la melanocortine-4 |
WO2007096186A1 (fr) * | 2006-02-23 | 2007-08-30 | Santhera Pharmaceuticals (Schweiz) Ag | Dérivés de phénylpipéridine substituée servant de modulateurs du récepteur de la mélanocortine-4. |
EP2019100A1 (fr) * | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Dérivés substitués d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
CA2743489A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituees pour le traitement du diabete |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (fr) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Inhibiteurs inédits de la prolylcarboxypeptidase |
EP2579873A4 (fr) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | Nouveaux inhibiteurs de prolylcarboxypeptidase |
WO2012100342A1 (fr) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine et dérivés de pyrazolopyrimidine en tant que modulateurs du récepteur de la mélanocortine-4 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK704488D0 (da) * | 1988-12-19 | 1988-12-19 | Novo Industri As | Nye n-substituerede azaheterocykliske carboxylsyrer |
US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5721250A (en) * | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5783582A (en) * | 1994-07-20 | 1998-07-21 | Merck & Co., Inc. | Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone |
US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
EP0828754B1 (fr) * | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides favorisant la secretion de l'hormone de croissance |
AU7710596A (en) * | 1995-11-29 | 1997-06-19 | Nihon Nohyaku Co., Ltd. | Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides |
GB9612276D0 (en) * | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
US5804578A (en) * | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
US5877182A (en) * | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
US5965565A (en) * | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
CA2377369A1 (fr) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4 |
WO2001034150A1 (fr) * | 1999-11-12 | 2001-05-17 | Merck & Co., Inc. | Derives de diaryle pyrrole piperidyle a amine aliphatique substitue utilises comme agents antiprotozoaires |
AU4929601A (en) * | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
EP1320366A4 (fr) * | 2000-08-23 | 2005-04-06 | Merck & Co Inc | Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine |
EP1370211A4 (fr) * | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | Co-administration de l'agoniste du recepteur de la melanocortine et inhibiteur de phosphodiesterase pour le traitement de troubles associes a l'amp cyclique |
WO2002079146A2 (fr) * | 2001-03-02 | 2002-10-10 | Bristol-Myers Squibb Company | Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci |
-
2003
- 2003-04-09 US US10/410,784 patent/US20040010010A1/en not_active Abandoned
- 2003-04-11 PE PE2003000371A patent/PE20040375A1/es not_active Application Discontinuation
- 2003-04-16 RU RU2004134719/04A patent/RU2004134719A/ru not_active Application Discontinuation
- 2003-04-16 JP JP2004500874A patent/JP2005525410A/ja not_active Withdrawn
- 2003-04-16 BR BR0309748-0A patent/BR0309748A/pt not_active IP Right Cessation
- 2003-04-16 WO PCT/US2003/011537 patent/WO2003092690A1/fr not_active Application Discontinuation
- 2003-04-16 KR KR10-2004-7017451A patent/KR20040104671A/ko not_active Application Discontinuation
- 2003-04-16 CN CNA038122235A patent/CN1655785A/zh active Pending
- 2003-04-16 TW TW092108827A patent/TW200404543A/zh unknown
- 2003-04-16 CA CA002483806A patent/CA2483806A1/fr not_active Abandoned
- 2003-04-16 MX MXPA04010762A patent/MXPA04010762A/es unknown
- 2003-04-16 EP EP03728400A patent/EP1499314A1/fr not_active Withdrawn
- 2003-04-16 PL PL03373575A patent/PL373575A1/xx not_active Application Discontinuation
- 2003-04-16 AU AU2003234094A patent/AU2003234094B2/en not_active Ceased
- 2003-04-29 AR ARP030101501A patent/AR039780A1/es not_active Application Discontinuation
-
2004
- 2004-10-19 IL IL16469704A patent/IL164697A0/xx unknown
- 2004-10-21 ZA ZA200408528A patent/ZA200408528B/en unknown
- 2004-10-27 MA MA27917A patent/MA27593A1/fr unknown
- 2004-11-24 NO NO20045126A patent/NO20045126L/no not_active Application Discontinuation
-
2005
- 2005-06-30 US US11/172,059 patent/US20050239835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1499314A1 (fr) | 2005-01-26 |
ZA200408528B (en) | 2005-07-07 |
TW200404543A (en) | 2004-04-01 |
CA2483806A1 (fr) | 2003-11-13 |
BR0309748A (pt) | 2005-02-15 |
PE20040375A1 (es) | 2004-08-05 |
US20040010010A1 (en) | 2004-01-15 |
JP2005525410A (ja) | 2005-08-25 |
US20050239835A1 (en) | 2005-10-27 |
CN1655785A (zh) | 2005-08-17 |
WO2003092690A1 (fr) | 2003-11-13 |
AU2003234094A1 (en) | 2003-11-17 |
KR20040104671A (ko) | 2004-12-10 |
AR039780A1 (es) | 2005-03-02 |
PL373575A1 (en) | 2005-09-05 |
IL164697A0 (en) | 2005-12-18 |
RU2004134719A (ru) | 2005-06-27 |
AU2003234094B2 (en) | 2006-03-09 |
MXPA04010762A (es) | 2005-03-07 |
NO20045126L (no) | 2005-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27593A1 (fr) | Derives de n-acyle piperidine utilises comme ligands du recepteur de la melanocortine dans le traitement de troubles de l'alimentation. | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA27883A1 (fr) | Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
MA27647A1 (fr) | Antagonistes de ccr5 utiles comme agents therapeutiques | |
CA2352405A1 (fr) | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
ATE306261T1 (de) | Antithrombosemittel | |
MA27569A1 (fr) | Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases | |
EP1797878A3 (fr) | Dérivés de benzothiazoles | |
DE69931393D1 (de) | Antithrombotische amide | |
ATE297203T1 (de) | Antithrombotische mitteln | |
TNSN04137A1 (fr) | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases | |
JP2004501962A (ja) | 銅含有アミン・オキシダーゼの阻害剤 | |
MA30142B1 (fr) | Agonistes du recepteur de neuropeptide-2 | |
TNSN97044A1 (fr) | Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. | |
TNSN05309A1 (fr) | Derives d'imidazole utilises comme antagonistes du recepteur du glutamate | |
DE602005022572D1 (de) | Antagonisten des opioidrezeptors | |
TNSN04212A1 (fr) | Sels de tolterodine | |
MA26541A1 (fr) | Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines | |
ATE399164T1 (de) | Antagonisten des opioidrezeptors | |
MA27130A1 (fr) | Nouveau procede de synthese de derives de l'acide (2s,3as,7as)-1-[(s)-alanyl]-octahydro- 1h-indole-2-carboxylique et application a la synthese du perindopril | |
WO2005080319A1 (fr) | Derives d'hydrazino alcool utiles en tant qu'inhibiteurs d'amine-oxydases contenant du cuivre | |
CO4410330A1 (es) | Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida | |
EA200600866A1 (ru) | Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний |